scholarly journals Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation

2011 ◽  
Vol 47 (4) ◽  
pp. 488-493 ◽  
Author(s):  
J Waterman ◽  
L Rybicki ◽  
B Bolwell ◽  
E Copelan ◽  
B Pohlman ◽  
...  
Keyword(s):  
Risk Factor ◽  
Stem Cell ◽  
Follicular Lymphoma ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Cell Harvest ◽  
Autologous Hematopoietic Cell Transplantation

scholarly journals COVID-19 INFECTION IN A CANDIDATE FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT

JBMTCT ◽  
2020 ◽  
Vol 2 (1) ◽  
pp. 33-36
Author(s):  
Mateus Lavor Lira ◽  
Yara Ceres E Silva Ferreira Lima ◽  
Isaias Lima De Figueiredo Júnior ◽  
Osvaldo Pimentel Oliveira Neto ◽  
Isabella Araujo Duarte ◽  
...  
Keyword(s):  
Stem Cell ◽  
Case Report ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Hematopoietic Stem ◽  
Autologous Hematopoietic Cell Transplantation

The pandemic for the new coronavirus SARS-CoV-2 has been the causeof enormous challenges for the entire health system, especially in programs who dealwith Hematopoietic Stem Cell Transplantation (TCTH), since sequelae related to COVID-19 can be a hindrance to a possible HSCT. In case report, VBF, 61 years old, diagnosis of classic lymphocyte-rich Hodgkin'slymphoma in 2018 with initial treatment with ABVD, due to the return of the disease, an ICE regimen was started, but with disease progression after 5 cycles. Then, an IGEV scheme was started with a schedule of autologous hematopoietic cell transplantation, which took place in the third cycle in May / 2020. However, at the end of May / 2020, he was admitted to the emergency department with confirmation of SARS-Cov-2 infection by means of PCR of the nasal and oropharyngeal swab. He evolved during hospitalization with hypoxemic respiratory failure, mechanical ventilation and signs of secondary pulmonary infection, using multiple antimicrobial regimens, showing improvement and finally being extubated. However, he presented important pulmonary sequelae, with chest CT showing extensive cavitation in the left upper lobe and reticular opacities, with distortion of the pulmonary architecture. He was reassessed as to the possibility of autologous hematopoietic cell transplantation, but this was contraindicated due to pulmonary sequelae. In the case reported, the patient complied with the formal indication for HSCT, which would be refractoriness or relapse in a second remission in patients up to 70 years old with sensitivity to rescue schemes. However, due to pulmonary sequelae acquired after COVID-19, HSCT was contraindicated. This case leads us to the conclusion that the pandemic by the SARS-CoV-2 coronavirus can directly affect HSCT services and that in addition to preventing infection in this group of patients, they should be reevaluated after the recovery of COVID-19 for evaluation of structural and functional respiratory sequelae.

The Role of Hematopoietic Stem Cell Transplant in Follicular Lymphoma

2010 ◽  
Vol 8 (3) ◽  
pp. 337-345 ◽  
Author(s):  
Edward A. Faber ◽  
Julie M. Vose
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Follicular Lymphoma ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Cell Transplant ◽  
Hematopoietic Stem

Substantial progress has been made in the clinical management of patients with follicular lymphoma over the past 2 decades. However, the role of autologous and allogeneic stem cell transplantation in these patients remains controversial. Myeloablative chemotherapy or radioimmunotherapy supported by autologous hematopoietic cell transplantation has been shown to lead to a longer progression-free survival and, in some studies, improved survival over standard therapy. However, in the era of rituximab-based therapies used as part of induction or salvage, these historical trials may not be representative. Allogeneic stem cell transplantation offers the advantages of a tumor-free graft and some immunologic graft-versus-lymphoma effects. However, fully myeloablative transplants have high morbidity and mortality rates. Dose-reduced conditioning regimens followed by allogeneic hematopoietic cell transplantation have substantially reduced treatment-related mortality and perhaps will produce better outcomes long-term. This article outlines some historical information regarding stem cell transplantation for follicular lymphoma and discusses recent modifications that may improve outcomes, such as adding radioimmunotherapy to autologous stem cell transplantation or using alternative dose-reduced regimens that could benefit patients with reduced toxicities.

scholarly journals Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantation

2016 ◽  
Vol 57 (8) ◽  
pp. 1781-1785 ◽  
Author(s):  
Heather Landau ◽  
Kevin Wood ◽  
David J. Chung ◽  
Guenther Koehne ◽  
Nikoletta Lendvai ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cell Transplantation ◽  
Plasma Cell ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Plasma Cell Myeloma ◽  
Autologous Hematopoietic Cell Transplantation

Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age

2017 ◽  
Vol 17 (3) ◽  
pp. 165-172 ◽  
Author(s):  
Binod Dhakal ◽  
Ariel Nelson ◽  
Guru Subramanian Guru Murthy ◽  
Raphael Fraser ◽  
Daniel Eastwood ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Effect Of Age ◽  
Autologous Hematopoietic Cell Transplantation

Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older

Cancer ◽  
2021 ◽  
Author(s):  
Pashna N. Munshi ◽  
David H. Vesole ◽  
Andrew St. Martin ◽  
Omar Davila ◽  
Shaji Kumar ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Autologous Hematopoietic Cell Transplantation

Longitudinal Assessment of Hematopoietic Abnormalities After Autologous Hematopoietic Cell Transplantation for Lymphoma

2005 ◽  
Vol 23 (27) ◽  
pp. 6699-6711 ◽  
Author(s):  
Ravi Bhatia ◽  
Khristine Van Heijzen ◽  
Ann Palmer ◽  
Asako Komiya ◽  
Marilyn L. Slovak ◽  
...  
Keyword(s):  
Stem Cells ◽  
Telomere Length ◽  
Cell Transplantation ◽  
Hodgkin’S Lymphoma ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Hodgkin's Lymphoma ◽  
Autologous Hct ◽  
Prospective Longitudinal ◽  
Autologous Hematopoietic Cell Transplantation

Purpose Autologous hematopoietic cell transplantation (HCT) is being increasingly used as an effective treatment strategy for patients with relapsed or refractory Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL) but is associated with therapy-related myelodysplasia and acute myeloid leukemia (t-MDS/AML) as a major cause of nonrelapse mortality. The phenomenon of hematopoietic reconstitution after autologous HCT and the role of proliferative stress in the pathogenesis of t-MDS/AML are poorly understood. Patients and Methods Using a prospective longitudinal study design, we evaluated the nature and timing of alterations in hematopoietic progenitors and telomere length after HCT in patients undergoing autologous HCT at City of Hope Cancer Center (Duarte, CA). Results A significant reduction in primitive and committed progenitors was observed before HCT compared with healthy controls. Further profound and persistent reduction in primitive progenitors but only transient reduction in committed progenitors were seen after HCT. Primitive progenitor frequency in pre-HCT marrow and peripheral-blood stem cells predicted for primitive progenitor recovery after HCT. Shortening of telomere length was observed in marrow cells early after HCT, with subsequent restoration to pre-HCT levels. Patients within this cohort who developed t-MDS/AML had reduced recovery of committed progenitors and poorer telomere recovery, possibly indicating a functional defect in primitive hematopoietic cells. Conclusion Our studies suggest that hematopoietic regeneration after HCT is associated with increased proliferation and differentiation of primitive progenitors. Increased proliferative stress on stem cells bearing genotoxic damage could contribute to the pathogenesis of t-MDS/AML. Extended follow-up of a larger number of patients is required to confirm whether alterations in progenitor and telomere recovery predict for increased risk of t-MDS/AML.

scholarly journals Outcomes of autologous hematopoietic cell transplantation in primary amyloidosis after bortezomib-based induction therapy

2016 ◽  
Vol 51 (5) ◽  
pp. 732-734 ◽  
Author(s):  
S Hong ◽  
J Valent ◽  
L Rybicki ◽  
D Abounader ◽  
B Bolwell ◽  
...  
Keyword(s):  
Cell Transplantation ◽  
Induction Therapy ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Primary Amyloidosis ◽  
Autologous Hematopoietic Cell Transplantation
Sign in / Sign up

Export Citation Format

Share Document